

Singapore breaks ground to build new Health Sciences Authority (HSA) building

07 October 2024 | News

Next phase of automating and digitalising operations



Singapore's Health Sciences Authority had a ground breaking ceroony on 7 October 2024, to begin building new HSA building.

Chairman, Prof Benjamin Ong graced the ceremony as Guest of Honour.

This project cements decade-long of planning, and will now move on to the next phase of automating and digitalising operations, emboding dedication to environmental sustainability and innovation and bring together all HSA colleagues from 5 current different locations into the new building once completed.

On September 12th, the Health Sciences Authority (HSA) announced the appointment of a new CEO effective from December 13, 2024. Adjunct Associate Professor Chua has been named HSA's CEO-designate. MOH and HSA said in a joint press release that he will succeed Dr Mimi Choong May Ling, who will retire from public service on Dec 13.

Adjunct Associate Professor Chua is currently the Deputy Director-General of Health (Health Regulation) at the Ministry of Health (MOH). In his role at MOH, he oversees the regulations of healthcare services and information in Singapore.

He will continue with this appointment alongside his new role as CEO of HSA "to better synergise regulatory operations and enforcement across healthcare services, information and products", said MOH and HSA.

Adjunct Associate Professor Chua has led multiple regulatory initiatives at MOH, including the enactment and implementation of the Human Biomedical Research Act and Healthcare Services Act. These Acts modernised the healthcare regulatory framework and enabled new modes of service delivery. He also established regulatory sandboxes for services such as telemedicine, mobile inpatient care-at-home and clinical genomic medicine services.

Adjunct Associate Professor Chua also played a key role during the COVID-19 pandemic, serving as Deputy Commander for the Medical Operations Taskforce and supporting COVID-19 clinical operations. He is also an Adjunct Associate Professor with the Saw Swee Hock School of Public Health at the National University of Singapore (NUS) and the Centre of Regulatory Excellence at Duke-NUS. Prior to his appointment in MOH, Adjunct Associate Professor Chua was the Group Director of the Health Products Regulation Group at HSA.